A study published in Clinical Infectious Diseases suggests that early use of monoclonal antibody (mAb) was linked with a reduction in hospital admissions and mortality among high-risk outpatients with COVID-19.

A retrospective review of medical records of patients referred to a COVID-19 clinic between November 1, 2020 and February 28, 2021 was conducted that included 617 high-risk patients. All high-risk outpatients were offered casirivimab/imdevimab or bamlanivimab within 5 days of diagnosis. Overall, 175 patients were administered mAb (83.4% received casirivimab/imdevimab, 16.6% received bamlanivimab). Patients who received mAb had lower odds of being hospitalized in comparison with those in the control group (1.7% vs 24%) with an odds ratio (OR) of 0.0466 after adjustment for risk score and local pandemic intensity. No COVID-19-related deaths were noted in the mAb group while there were12 deaths (2.7%) in the control group… (DG Alerts)